Some uncommon and perhaps surprising applications of common treatments are in the works.
FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause
The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.
Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps
Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.
Menopause Education Lags in Residency Training Across Primary Care Specialties
Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.
Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes
Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.
Menopause Education Wholly Inadequate for Physician Associates, According to New Survey Results
Only 3% of physician associate respondents reported receiving more than 5 hours of menopause-related training during their professional education.
APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause
Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.